Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • Wednesday
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/19/26
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Zacks Investment Research • 10/19/26
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyGlobeNewsWire • 10/19/26
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026GlobeNewsWire • 10/12/26
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026GlobeNewsWire • 10/02/26
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic CardiomyopathyGlobeNewsWire • 09/30/26
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein ConferenceMarketBeat • 09/25/26
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant ProgramGlobeNewsWire • 09/14/26
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026GlobeNewsWire • 08/29/26
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM TranscriptSeeking Alpha • 08/28/26
Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol MyersInvestors Business Daily • 08/28/26
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of MedicineGlobeNewsWire • 08/28/26
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700The Motley Fool • 08/22/26
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026GlobeNewsWire • 08/20/26